Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?

Basit Öğe Kaydı
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorKars, Taha Ulutan
dc.contributor.authorTuna, Ali Kursat
dc.contributor.authorKilinc, Ibrahim
dc.contributor.authorDemircioglu, Sinan
dc.contributor.authorCeneli, Ozcan
dc.date.accessioned2024-02-23T14:31:54Z
dc.date.available2024-02-23T14:31:54Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjectives We measured the serum periostin levels in patients with DLBCL and determined whether the levels reflected the clinical findings. Methods This was a case-control study. DLBCL patients diagnosed between March 2021 and October 2021 (n=36) and healthy volunteers (n=36) (Control group) were included. The serum periostin levels of the two groups were compared. Moreover, subgroup analyses were conducted in the patient group. Results The serum periostin level was significantly higher in the patient than the control group (28.8 +/- 3.2 vs. 15.1 +/- 7.5 ng/mL, p=0.017). On subgroup analyses, the median serum periostin level of nine (25%) patients with bone marrow involvement was higher than that of the 27 (75%) lacking bone marrow involvement (12.7 vs. 21.7 ng/mL, p=0.018). On ROC analysis, the optimal periostin cutoff for bone marrow involvement was 17.3 ng/mL (sensitivity 77%, specificity 67%, AUC 0.765; 95% CI; 0.606-0.924, p=0.018). By the disease stage, the periostin level was higher in stage 4 patients than in those of other stages (21.3 vs. 12.0 ng/mL, p=0.029). Conclusions The periostin level correlated with such involvement; periostin may serve as a novel prognostic marker of DLBCL.en_US
dc.identifier.doi10.1515/tjb-2022-0146
dc.identifier.endpage774en_US
dc.identifier.issn0250-4685
dc.identifier.issn1303-829X
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85146471861en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage770en_US
dc.identifier.urihttps://doi.org/10.1515/tjb-2022-0146
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15407
dc.identifier.volume47en_US
dc.identifier.wosWOS:000865829300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofTurkish Journal Of Biochemistry-Turk Biyokimya Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBone Marrow Involvementen_US
dc.subjectDiffuse Large B Cell Lymhpomaen_US
dc.subjectLaboratory Markersen_US
dc.subjectPeriostinen_US
dc.subjectPrognosisen_US
dc.titleMight periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu